UNSPSC 51393101: Aganodine

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H10Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 670P9AQR46, chemically known as guanidine, (4,7-dichloro-2-isoindolinyl)- but generally known as aganodine, which bears US NIH Compound Identifier 176878. European Medicines Agency schedules Aganodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05284MIG.

UNSPSC 51393101 Aganodine is a Commodity code covering pharmaceutical products and related medical supply systems procured by state and local health agencies. Based on recent solicitations, state and local governments buy naloxone (opioid-reversal medication) and drug deactivation systems under this code to support community health and public safety initiatives. Issuing bodies include county health departments and state health and human services commissions. The work spans direct product procurement with specified annual volumes and delivery schedules, as well as market-research activities to evaluate pharmacy benefit program structures and direct-to-manufacturer contracting models that may affect future pharmaceutical purchasing strategies.

Recent activity concentrates in Florida and Texas. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with a one-year renewal option and requires vendors to cover all shipping and delivery costs. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013, response deadline April 3, 2026) to gather vendor capabilities on implementing direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential shifts in how the state procures pharmaceuticals going forward.